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Abstract
Introduction: Having in mind the promising results of
lymphoscintigraphy and intraoperative gamma probe
application for the detection of sentinel lymph nodes
(SLN) in malignant melanoma, breast and penis cancer,
we tried to identify the SLN in prostate cancer by
applying a comparable technique. Materials and Meth-
od: 350 patients with prostate cancer were examined
after providing informed consent. The day before pelvic
lymphadenectomy technetium-99m nanocolloid was
transrectally injected into the prostate under ultrasound
guidance. A single central application was done per
prostate lobe in most cases. Activity attained 90–
400 MBq, and the total injected volume was about 2–3
ml. Hereafter, lymphoscintigraphy was carried out.
Those lymph nodes having been identified as SLN by
means of gamma probe detection and lymphoscintigra-
phy were removed intraoperatively. Later, most of the
cases had different types of pelvic lymphadenectomy.
SLN received serial sections and immunohistochemis-
try, non-SLN step sections. Results: 335 patients showed
at least 1 SLN in lymphoscintigraphy. 24.7% had lymph
node metastases. In 2 patients, metastases in non-SLN
were found without at least one SLN being affected
(false-negative patient). Conclusion: Our experience sug-
gests that the SLN identification is not only feasible in
breast cancer and malignant melanoma, but also in pros-
tate cancer with a comparable technique.
Copyright © 2003 S. Karger AG, Basel
Introduction
The first papers about lymphoscintography of the hu-
man prostate were published in the late 1970s and early
1980s [1–4]. Previous investigations had the objective to
prove the presence of an intraprostatic lymphatic system
and the imaging of regional lymphatic drainage from the
prostate. Gardiner et al. [1] were the first to demonstrate
lymphatic pathways by transrectal injection with a
99mTc-labelled tracer (particle size 4–12 nm) into the pros-
tate capsule. Transperineal injection into the parenchyma
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99mTc-Nanocoll
RVL 30 min RVL 3 h
Fig. 1. Typical prostate lymphoscintigraphy
with early (30 min) and delayed (3 h) imag-
ing. Multiple sentinel (black arrows) and
subordinated lymph nodes.
99mTc-Nanocoll
March 08, 1999
RVL 20 min RVL 20 min
RVL 2 H RVL 2H
March 25, 1999
Fig. 2. A repeated prostate lymphoscintigra-
phy (the day of surgery had to be postponed
for unforeseen reasons) with identical SLN
location (black and white arrow).
as well as open and periprostatic injection were not suc-
cessful. In all 40 patients with injections close to the cap-
sule a uni- or bilateral lymph drainage was shown. In
1990, Zuckier et al. [5] were able to show partly contralat-
eral, pelvic lymphatic drainage in 8 of 9 patients with
prostate cancer using a comparable technique. A single
patient needed a repeated injection under similar condi-
tions and showed an identical lymphatic drainage.
Whether it was possible to depict the entire lymphatic
drainage of the prostate remains unclear, because opera-
tive and histological reviews on patients were not carried
out.
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After the intended verification of metastases by pros-
tate lymphoscintography failed, it was not developed any
further in the 1990s. Only after the clinically important
combination of preoperative lymphoscintigraphy and in-
traoperative gamma-probe measuring took place, similar
to the procedure in breast cancer and malignant melano-
ma, did the method experience a revival [6, 7].
Patients and Method
Patients
Between July 1998 and October 2001, 350 patients with prostate
cancer were examined after providing informed consent. Special cri-
teria for the selection of the patient population were not applied. Pre-
operative total body bone scanning of the pelvis showed normal
findings in all patients. The average preoperative PSA level was
12.7 ng/ml.
Tracer Injection
The day before pelvic lymphadenectomy technetium-99m nano-
colloid (Nanocoll®, Sorin Co., Italy) was applied transrectally into
the prostate under ultrasound guidance. The interval between injec-
tion and surgery varied between 18 and 22 h. A 1-day protocol was an
exception. A single central application was done per prostate lobe,
rarely two. Depending on the interval between injection and surgery
the chosen activity attained 90–400 MBq (median 267.3 MBq) and
the total injected volume was about 2–3 ml.
Prostate Lymphoscintigraphy
In the beginning, approximately 30 min later and a few hours
after injection, scintigraphy (Sopha camera, DSX, Leap collimator)
was performed in anteroposterior projections (fig. 1, 2), and in single
case lateral views. The prostate was, in part, covered during this pro-
cedure. Later the taking of early images was abandoned, because they
did not supply additional information about SLN identification. Ini-
tially, the SLN were noticed to be covered by the inevitable overflow
of radioactivity into the urine of the bladder, especially in the early
images. This problem was reduced by transurethral catheterization.
After early imaging was abandoned this measure was unnecessary.
Operative Procedure
In relation to the intended therapy of prostate cancer (e.g. radio-
therapy, perineal or retropubic prostatectomy), pelvic lymphadenec-
tomy was carried out via different surgical accesses (table 1). In the
majority of patients a lymphadenectomy was directly followed by
radical retropubic prostatectomy (n = 282). In the beginning, all
patients received sentinel lymphadenectomy (SLNE) plus the dissec-
tion of the lymph nodes from the obturator fossa and the external
iliac lymph nodes (so-called modified lymphadenectomy). Analysis
after 121 patients [7] showed that sentinel lymphadenectomy alone
in comparison to modified lymphadenectomy has a sensitivity of
about 96%. This result was statistically significant (p ! 0.05) com-
pared to resection of the obturator lymph nodes only. Subsequently,
we modified our study protocol. In the following, the extent of pelvic
lymphadenectomy varied depending on the preoperative risk factors
between SLNE only (PSA !10 ng/ml, Gleason Score !7 in biopsy
and clinical stage !T3) and SLNE with additional extended pelvic
Table 1. Different surgical approaches of
pelvic lymphadenectomy
Surgical approach Cases
Laparotomy 272
Minilaparotomy 69
Laparoscopy 7
Total 348
Table 2. Extension of pelvic lymphadenectomy
Extension of pelvic lymphadenectomy Cases
Sentinel lymphadenectomy 129
Sentinel lymphadenectomy plus modified pelvic
lymphadenectomy 121
Sentinel lymphadenectomy plus extended
lymphadenectomy 94
Pick-up lymphadenectomy 4
Total 348
lymphadenectomy (PSA 110 ng/ml, Gleason Score 16 in biopsy or
clinical stage 1T2) (table 2). Two cases received no operation after
lymphoscintigraphy.
The radioactivity of the lymph nodes was measured intraopera-
tively by different gamma probes (C-TRAK system, Car-Wise, Mor-
gan Hill, Calif., USA and Szintiprobe MR-100, pol. hi. tech., Italy).
The identification technique was similar to that used in other tumor
entities.
Results
Patients and Lymph Node Histology
Allergic or septic complications did not occur during
perioperative antibiotic prophylaxis with a chinolon deri-
vate. In the absence of rectal disease (e.g. anal fissure) the
injection was well tolerated.
86 of 348 patients (24.7%) had lymph node metastases.
SLN received serial sections (5 systematically distributed
sections of 4 Ìm between each step section) and immuno-
histochemistry (IHC, pancytokeratin antibody), non-SLN
step sections of approximately 2 mm. In 2 patients, lymph
node metastases in non-SLN were shown without a single
SLN being affected. The incidence of node-positive pa-
tients depends on preoperative prostate-specific antigen
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Fig. 3. Whole-body scan with distribution of
radioactivity into the liver (L), bladder (B),
prostate (P), and SLN (black arrows).
99mTc-Nanocoll
20 min p.i. 17 h p.i.
L
B
P
RVL LDR RVL LDR
Table 3. Lymph node status depending on preoperative prostate spe-
cific antigen (PSA) level (a) and tumor classification of the prostatec-
tomy specimen (b)
a
PSA, ng/ml Cases Node-positive patients
0–4 19 2
14–10 168 29
110–20 113 33
120 50 22
Sum 350 86
b
Tumor classification Cases Node-positive patients
T1,2a,b 171 26
T3a 55 15
T3b 40 28
T4 16 11
Sum 282 80
(PSA) and tumor classification of the prostatatectomy
specimen (table 3a, b).
69.8% of the node-positive cases had no positive non-
SLN and approximately 2 of 3 had only one positive
SLN.
Prostate Lymphoscintigraphy
In 92.6% of the patients at least a single SLN was
revealed in lymphoscintigraphy. Prostate lymphoscintig-
raphy seemed only to be influenced by a neoadjuvant hor-
monal therapy provided it was the selected treatment over
a longer period of time (13 months). In 10 randomly
selected patients the determination of radionuclide distri-
bution (fig. 3) and its time course was made via ‘Regions
of Interest’ (ROIs) over prostate, bladder, liver, spleen
and the SLN [8] (table 4). This revealed a high interindi-
vidual variance of uptake.
The depiction of lymphatic pathways was only possible
in 11.1% of the cases. The essential SLN criteria were the
persisting accumulation of activity and the anatomical
localization.
Intraoperative SLN Identification
In 10 patients it was not possible to identify at least one
SLN (2.9%) intraoperatively: one patient received neoad-
juvant hormonal therapy for 3 years, 2 had laparoscopic
surgery, and 3 had transurethral or transvesical prostate
surgery for benign enlargement before. In 4 cases no rea-
son was obvious. In an additional 5 patients, the intra-
operative measuring was not applied (e.g. local advanced
disease) or not completed (e.g. macrometastases). Of 23
patients who had a previous transurethral resection or
transvesical prostatectomy 4 showed no SLN. The limita-
tion was significant (· ! 0.005, ¯ 2 test).
We dissected an average of 5.6 SLN and 12.4 non-
SLN. Of those patients with at least one SLN, 78.9% had
between 2 and 8 SLN (fig. 4). There was no significant
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Fig. 4. Number of SLN in each patient.
(Mann-Whitney test) dependence on the number of SLN,
tumor stage, and number of SLN in node-positive and
-negative patients (5.8 vs. 5.5 SLN).
All radioactive lymph nodes which could not be clearly
identified as a subordinated lymph node on the basis of
the anatomical localization and knowledge of the lym-
phoscintigraphy were classed as SLN. In 78.6%, the num-
ber of intraoperatively identified SLN exceeded the ones
determined by scintigraphy. In 16.4% of the cases dissec-
tion of all SLN was impossible. Mostly, this was the case
in laparoscopy (6 of 7 cases) or minilaparotomy (16 of 69
cases). Non-resectable or reidentifiable SLN were mostly
located in areas which were difficult to access surgically
(internal iliac region, pararectal, presacral).
Discussion
Lymph node metastases are relatively often revealed in
supposedly localized prostate cancers at the time of sur-
gery. Data for the frequency of this manifestation differ
largely depending on the treated population and the
extent and technique of pelvic staging lymphadenecto-
my.
While large US studies revealed lymph node-positive
stages in only 12% [9], we detected lymph node metas-
tases in nearly 24.7% in our own investigation, despite
inconspicuous preoperative imaging (CT, MRI).
The lymph node status in prostate cancer is not only of
prognostic but also of tremendous therapeutic relevance,
since common standards still include the renunciation of
local curative therapy (e.g. radical prostatectomy, radio-
therapy) in case of positive lymph node findings and pos-
Table 4. Average uptake (%) of different
organs in prostate lymphoscintigraphy
Organ Average uptake
% (range)
Prostate 15.8 (7.7–28)
Bladder 24.5 (4.3–47)
Liver 25 (12.2–47.2)
Spleen 2.1 (0.7–3.6)
Bone marrow 32 (21.9–54.2)
Sentinel lymph nodes 0.12 (0.007–0.63)
tulate hormonal withdrawal [10]. Thus, all techniques for
the identification of metastases should have a high sensi-
tivity (in order to avoid unnecessary and stressful treat-
ment) and a high specificity (in order not to deprive a
patient of a promising curative treatment).
Pelvic lymphadenectomy is presently considered the
method of choice for the identification of lymph node
metastases in prostate cancer [11]. Alternative techniques
for a sufficient prediction of lymph node micrometastases
have not been developed. Pelvic CT scans and MRI do
not give certainty on the presence of lymph node microm-
etastasis [12]. Even radioimmunoscintigraphy with in-
dium-111-capromab pendetide is presently not able to
replace pelvic lymphadenectomy, showing a positive pre-
dictive value for a high-risk collective of only 66.7% [13].
This is also the case for the application of positron emis-
sion tomography with fluorine-18 fluorodeoxyglucose, in
which a large number of micrometastases remain unde-
tected [14, 15].
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Table 5. Published complication rates of
pelvic lymphadenectomy Author Patients Complication
rate, %
Type of
lymphadenectomy
Paul et al. [16], 1983 150 51 extended open
Mc. Dowell et al. [18], 1990 217 22 extended open
Schuessler et al. [17], 1993 147 31 extended laparoscopic
Stone et al. [26], 1997 150 35.9 extended laparoscopic
39 2 modified laparoscopic
Lezin et al. [27], 1997 22 9.1 modified minilaparotomy
22 31.8 modified laparoscopic
Fahlenkamp et al. [28], 1997 200 12.5 modified laparoscopic
Herrell et al. [29], 1997 38 20 modified open
Table 6. Incidence of node-positive patients depending on preoperative risk factors
Preoperative risk factors Patients Node-positive patients
n %
PSA !10 ng/ml and ! cT3 and Gleason score in biopsy !7 153 18 11.8
PSA 110 ng/ml or 1 cT2 or Gleason score in biopsy 16 197 68 34.5
Homogeneous surgical standards of pelvic staging lym-
phadenectomy for prostate cancer cannot be gathered
from the current literature. Because of the high morbidity
due to extended pelvic lymphadenectomy (table 5) and
the operating time of an average 2.5 h [16] the area of
dissection has been decreased at most centers. Published
data of extended pelvic lymphadenectomy in prostate
cancer [17, 18, 19] point out that any limitation of the
dissection area corresponds with a reduced detection rate
of micrometastases. The widespread limitation of the dis-
section area to the so-called obturator fossa lymph nodes
results in missing about 50% of the lymph-node-positive
patients [17]. This and the at times surgically rather diffi-
cult accessible locations (presacral, pararectal, paravesi-
cal, hypogastric lymph nodes) of the primarily draining
lymph nodes of the prostate explain the clinical need of
radio guided lymph node surgery in prostate cancer.
The SLN identification in prostate cancer is different
on principle from the techniques in other tumor entities.
In breast cancer, penile cancer and malignant melanoma
mostly a well-placed peritumoral injection is carried out,
only to demonstrate the lymphatic drainage from the
tumor. In prostate cancer, however, it is not known preop-
eratively which part of the organ the metastatic spread is
originating from. Therefore, the principle aim has to be
the identification and resection of all primarily draining
lymph nodes, inevitably comprising a single or more
SLNs of the tumor.
There are numerous explanations for the number of
intraoperatively identified SLN exceeding the ones found
preoperatively in lymphoscintigraphy.
(1) Following precise preparation, single hot spots
proved to be several neighboring radioactive lymph
nodes.
(2) Overlapping radioactivities of lymph nodes from
different levels.
(3) Lymph nodes closely related to the prostate are cov-
ered by intraprostatic activity.
(4) Delayed lymphatic drainage following lymphoscin-
tigraphy.
Furthermore, it is not possible to demonstrate for eve-
ry single radioactive lymph node, whether it is a primarily
draining lymph node or a subordinate. This is explained
by the mostly absent lymphatic pathways and the particu-
larly delayed lymphatic drainage. However, this problem
is of minor clinical relevance, because only in 14.3% of
the patients more than 8 SLN were identified. The aver-
age number and location of the identified SLN corre-
sponds with anatomical descriptions of the prostatatic
lymphatic drainage in humans.
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Our experiences with this novel technique point out
the necessity of preoperative lymphoscintigraphy since
the minimal number of SLN to be detected intraopera-
tively is determined by this method. Furthermore, it is
easier to locate obscured and surgically difficult accessible
lymph nodes intraoperatively. This is valid especially in
minimal invasive surgery.
Our investigation demonstrates that the number of
lymph-node-positive patients is considerably larger than
mentioned in the current literature [9]. Even with com-
paratively favorable preoperative prognostic factors (PSA
!10 ng/ml, clinical stage !T3, and Gleason Score !7 in
prostate biopsy) we found lymph node metastases in
11.8% of the cases (table 6), although staging lymphaden-
ectomy is no standard option. In addition, the individual
variability of the lymphatic drainage and in case of lim-
ited dissection area the reduced sensitivity for detecting
node-positive patients is obvious: approximately 60%
would be missed with the customary pelvic lymphadenec-
tomy limited to the lymph nodes in the obturator fossa
(table 7).
In principle during the period of validation it has to be
realized that to determine the sensitivity of a procedure a
comparably extended lymphadenectomy has to be carried
out. Additionally, all lymph nodes have to be examined
with the same histopathological technique. As we investi-
gated all sentinel lymph nodes in this study with IHC and
serial sections, we consciously give no sensitivity. Taking
Table 7. Identified node-positive patients depending on the exten-
sion of pelvic lymphadenectomy (based on the results of sentinel
lymphadenectomy, with or without additional pelvic lymphadenec-
tomy and with serial sections and immunohistochemistry of all senti-
nel lymph nodes, non-SLN received step sections); 95% CI
Region of lymphadenectomy Node-positive
patients, %
Obturator fossa, external and internal iliac region,
presacral, pararectal, paravesical 100
Obturator fossa, external and internal iliac region 96.5
Obturator fossa, internal iliac region 79*
Obturator fossa, external iliac region 75.6**
Obturator fossa 40.7**
* Significant for p ! 0.05; ** significant for p ! 0.01.
into account the above-mentioned criteria, the sensitivity
of sentinel lymphadenectomy alone varied between 93.1
[30] and 96% [7].
Improving the accuracy of the preoperative SLN iden-
tification (e.g. visualization of lymphatic pathways, de-
crease of SLN count rate, increase of urine contamina-
tion) based on the evaluation of different parameters (e.g.
radiopharmaceutical, injection site, injection volume)
must be the most important goal of further investiga-
tions.
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